Join the 'Baraclude' group to help and get support from people like you. How it works
Baraclude Blog
| Tweet |
HIV Drugs May Be Tied to Early Aging
Posted 27 Jun 2011 by Drugs.com
SUNDAY, June 26 – An older class of antiretroviral drugs used to treat HIV can cause premature aging, a new study suggests. Researchers examined muscle cells from HIV patients and found that zidovudine (AZT) and other antiviral drugs known as nucleoside analogue reverse-transcriptase inhibitors (NRTIs) damage DNA in mitochondria, the energy factories in cells. The study is published June 26 in the journal Nature Genetics. The finding may help explain why some HIV patients treated with antiviral drugs show advanced signs of frailty and age-related diseases such as dementia and cardiovascular disease at an early age. "HIV clinics were seeing patients who had otherwise been successfully treated but who showed signs of being much older than their years. This was a real mystery," Professor Patrick Chinnery, a senior fellow in clinical science at the Institute of Genetic Medicine at ... Read more
Related support groups: HIV Infection, Baraclude, Hepsera, Viread, Entecavir, Tenofovir, Epivir, Stavudine, Adefovir, Zidovudine, Lamivudine, Ziagen, Retrovir, Telbivudine, Abacavir
Baraclude Sanctioned for Severe Liver Disease
Posted 19 Oct 2010 by Drugs.com
MONDAY, Oct. 18 – Bristol-Myers Squibb said Monday its liver drug Baraclude (entecavir) has received expanded approval from the U.S. Food and Drug Administration to treat chronic hepatitis B in adults with decompensated liver disease, a form of severe liver damage. Baraclude was first approved in 2005 for adults with compensated liver disease, a less severe form of damage that means the liver still functions properly, the drug maker said in a news release. Decompensated liver disease, by contrast, refers to failure of the liver to maintain adequate function, commonly due to severe scarring. Chronic hepatitis B often causes chronic liver inflammation, which can lead to decompensated liver disease, the drug maker said. About 1.25 million Americans are infected with chronic hepatitis B, Bristol said. More information The U.S. National Digestive Diseases Information Clearinghouse has more ... Read more
Related support groups: Baraclude
Anti-HIV Drugs May Help Prevent Spread of Virus
Posted 27 May 2010 by Drugs.com
THURSDAY, May 27 – People who are HIV-positive can lower their risk for transmitting the virus to their partners by 90 percent by taking antiretroviral drugs, new research has found. Antiretroviral drug therapy helps reduce HIV levels in the infected person's blood, which in turn makes the person less infectious to others. The drugs are commonly taken in the United States by people with HIV, the virus that causes AIDS. In the new research, published online May 26 in The Lancet, investigators studied more than 3,400 heterosexual couples in seven African countries. In each couple, one person was infected with HIV and the other was not. No one in the study was taking antiretroviral drugs. Health workers counseled the couples about preventing HIV transmission and followed up with them for two years. During that time, periodic blood tests measured HIV levels in the blood, and people were ... Read more
Related support groups: HIV Infection, Atripla, Truvada, Baraclude, Kaletra, Entecavir, Norvir, Hepsera, Combivir, Lexiva, Ritonavir, Norvir Soft Gelatin, Viread, Trizivir, Tenofovir
FDA Medwatch Alert: Baraclude (entecavir) Tablets and Oral Solution
Posted 24 Feb 2007 by Drugs.com
[Posted 02/24/2007] FDA and Bristol-Myers Squibb notified healthcare professionals of revisions to the MICROBIOLOGY/Antiviral Activity and INDICATIONS AND USAGE/Description of Clinical Studies/Special Populations sections of the prescribing information for Baraclude. The revised labeling is the result of a case report in which a human immunodeficiency virus (HIV) variant containing the M184V resistance substitution was documented during Baraclude treatment for chronic hepatitis B virus (HBV) infection in an HIV/HBV co-infected patient who was not simultaneously receiving highly active antiretroviral therapy (HAART). Current treatment guidelines recommend Baraclude as an option for treatment of HBV in the HIV/HBV co-infected adult patient who does not qualify for HAART. Healthcare professionals are advised that when considering therapy with Baraclude in an HIV/HBV co-infected patient ... Read more
Related support groups: Baraclude